[New possibilities for immunoglobulin substitution in antibody deficiency syndrome].
The effect of an unmodified immunoglobulin for intravenous substitution in patients with antibody deficiency syndrome (ADS) has been studied. Over 100 doses of Sandoglobulin were administered to ADS patients without any sign of anaphylactoid reaction. There is no upper limit on the quantity infused. Peak values and basal values can be calculated and therapy can be adjusted accordingly. The halflife of the preparation equals that of native IgG in a healthy person. Comparing days with temperature above 38 degrees C (100.4 degrees F), days under antibiotics, and absence from work during equal periods with and without Sandoglobulin, the beneficial effect of this preparation is obvious. Sandoglobulin can be recommended for longterm therapy in ADS.
D000906:Antibodies / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*
D000906:Antibodies; D007136:Immunoglobulins
Neue Möglichkeiten der Immunglobulin-Ersatztherapie bei Antikörpermangel-Syndrom.